7.58
+19.37%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About aTyr Pharma
From its filings with the US Securities and Exchange Commission
aTyr Pharma is based in San Diego, California and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker ATYR. The SEC classifies its business as biological products, (no diagnostic substances). In the fiscal year to 31 December 2025, it reported revenue of $190,000 and a net loss of $74.1m. At that date it held total assets of $93.0m and shareholders' equity of $67.5m.
We are a clinical stage biotechnology company leveraging evolutionary intelligence to translate tRNA synthetase biology into new therapies for fibrosis and inflammation. tRNA synthetases are ancient, essential proteins that have evolved novel domains that regulate diverse pathways extracellularly in humans. Our discovery platform is focused on unlocking hidden therapeutic intervention points by uncovering signaling pathways driven by our proprietary library of domains derived from all 20 tRNA synthetases.
Our lead therapeutic candidate is efzofitimod, a novel biologic immunomodulator in clinical development for the treatment of interstitial lung disease (ILD), a group of immune-mediated disorders that can cause inflammation and fibrosis, or scarring, of the lungs. Efzofitimod is a tRNA synthetase derived therapy that selectively modulates activated myeloid cells through neuropilin-2 (NRP2) to resolve aberrant inflammation without immune suppression and potentially prevent the progression of fibrosis. ILDs are predominantly immune-mediated disorders that are characterized by chronic inflammation, which can lead to progressive fibrosis of the lung. There are limited treatment options for ILD and there remains a high unmet medical need. Sarcoidosis and systemic sclerosis (SSc, also known as scleroderma)-associated ILD (SSc-ILD) are two major forms of ILD. The U.S.
Quoted from its 10-K, filed 5 Mar 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 7 May 2015
- Employees
- 56
- Website
- atyrpharma.com ↗
- Head office
- 10240 SORRENTO VALLEY ROAD, SAN DIEGO, CA, 92121
- Incorporated in
- DE
- Classification
- Biological Products, (No Diagnostic Substances)
- Filer status
- Non-accelerated filer<br>Smaller reporting company
Leadership
Pay as last reported
- Mr. Timothy CoughlinIndependent Chairman of the Board$129,356
- Dr. Sanjay ShuklaPresident, Chief Executive Officer, Director, since 2016$1.5m
- Ms. Jill BroadfootChief Financial Officer$746,163
- Ms. Nancy DenyesGeneral Counsel, Corporate Secretary$729,305
- Mr. Eric BenevichIndependent Director$227,301
- Dr. Jane GrossIndependent Director$82,323
- Dr. Svetlana LucasIndependent Director$82,264
- Dr. Paul SchimmelIndependent Director$70,144
- Dr. Sara ZaknoenIndependent Director$80,263
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Unique pipeline: aTyr Pharma Inc has a strong portfolio of innovative therapeutics focusing on rare genetic diseases. The company's products have the potential to address unmet medical needs.
- Patented technology: aTyr's proprietary Physiocrine biology platform enables the discovery and development of protein-based therapeutics. This cutting-edge technology provides the company with a competitive advantage.
- Strong research and development capabilities: aTyr Pharma has a dedicated team of scientists and experts in biotechnology, ensuring the continuous development of novel drug candidates.
Weaknesses
- Limited market presence: aTyr Pharma Inc is a relatively small and emerging player in the pharmaceutical industry. This lack of market recognition may pose challenges in gaining widespread adoption of their products.
- Dependence on key partnerships: The company relies heavily on collaborations with research institutions and pharmaceutical companies for funding and expertise. Any disruption in these partnerships could impact aTyr's operations.
- High research and development costs: Developing new drugs and conducting clinical trials can be expensive. As a smaller company, aTyr Pharma may face financial constraints in advancing its pipeline at the desired pace.
Opportunities
- Growing demand for rare disease treatments: The pharmaceutical industry is increasingly focused on developing therapies for rare genetic disorders, presenting aTyr with opportunities to capture a niche market and address significant unmet medical needs.
- Strategic collaborations: Forming partnerships with larger pharmaceutical companies can provide aTyr with access to additional resources, funding, and expertise necessary for accelerated research and development.
- Expansion into global markets: As aTyr Pharma's products gain regulatory approvals, there is potential for international expansion, tapping into markets beyond the United States and increasing revenue streams.
Threats
- Competitive landscape: The pharmaceutical industry is highly competitive, with numerous established players and emerging biotech companies. aTyr Pharma faces the risk of larger competitors developing similar or superior products.
- Regulatory hurdles: The process of regulatory approvals for drug candidates involves significant time, costs, and uncertainties. aTyr Pharma may face challenges in obtaining necessary approvals, delaying product launches and revenue generation.
- Economic factors: Global economic fluctuations, healthcare reforms, or changes in reimbursement policies could impact the affordability and accessibility of aTyr's products, affecting market demand.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.